FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence

References

• 1 Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur. Urol. 45(5), 606–612 (2004).
  Medline CASGoogle Scholar
• 2 Birkhahn M, Mitra AP, Williams AJ et al. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur. Urol. 57(1), 12–20 (2010).
  Medline CASGoogle Scholar
• 3 Cheng L, Zhang S, Davidson DD et al. Molecular determinants of tumor recurrence in the urinary bladder. Future Oncol. 5(6), 843–857 (2009).
  CASGoogle Scholar
• 4 Dyrskjot L, Zieger K, Kruhoffer M et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin. Cancer Res. 11(11), 4029–4036 (2005).
  Medline CASGoogle Scholar
• 5 Zuiverloon TC, Beukers W, Van Der Keur KA et al. Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project. J. Urol. 189(5), 1945–1951 (2013).
  Medline CASGoogle Scholar
• 6 Anastasiadis A, Cordeiro E, Bus MT, Alivizatos G, De La Rosette JJ, De Reijke TM. Follow-up procedures for non-muscle-invasive bladder cancer: an update. Expert Rev. Anticancer Ther. 12(9), 1229–1241 (2012).
  Medline CASGoogle Scholar
• 7 Kamat AM, Hegarty PK, Gee JR et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur. Urol. 63(1), 4–15 (2013).
  MedlineGoogle Scholar
• 8 Burger M, Van Der Aa MN, Van Oers JM et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur. Urol. 54(4), 835–843 (2008).
  MedlineGoogle Scholar
• 9 Van Oers JM, Lurkin I, Van Exsel AJ et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin. Cancer Res. 11(21), 7743–7748 (2005).
  Medline CASGoogle Scholar
• 10 Babjuk M, Burger M, Zigeuner R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur. Urol. 64(4), 639–653 (2013).
  MedlineGoogle Scholar
• 11 Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21(18), 1315–1330 (2003).
  MedlineGoogle Scholar
• 12 Lokeshwar VB, Habuchi T, Grossman HB et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66(6 Suppl. 1), 35–63 (2005).
  MedlineGoogle Scholar
• 13 Todenhofer T, Hennenlotter J, Aufderklamm S et al. Individual risk assessment in bladder cancer patients based on a multi-marker panel. J. Cancer Res. Clin. Oncol. 139(1), 49–56 (2013).
  MedlineGoogle Scholar
• 14 Xylinas E, Kluth LA, Rieken M, Karakiewicz PI, Lotan Y, Shariat SF. Urine markers for detection and surveillance of bladder cancer. Urol. Oncol. 32(3), 222–229 (2013).
  MedlineGoogle Scholar
• 15 Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492), 315–322 (2014).
  MedlineGoogle Scholar
• 16 Gomez-Roman JJ, Saenz P, Molina M et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin. Cancer Res. 11(2 Pt 1), 459–465 (2005).
  Medline CASGoogle Scholar
• 17 Sung JY, Sun JM, Chang Jeong B et al. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy. Urol. Oncol. 32(1), 49.e23–31 (2014).
  CASGoogle Scholar
• 18 Liu X, Zhang W, Geng D, He J, Zhao Y, Yu L. Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis. Genet. Mol. Res. 13(1), 1109–1120 (2014).
  Medline CASGoogle Scholar
• 19 Millholland JM, Li S, Fernandez CA, Shuber AP. Detection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencing. Res. Rep. Urol. 4 33–40 (2012).
  Medline CASGoogle Scholar
• 20 Lopez-Beltran A, Requena MJ, Luque RJ et al. Cyclin D3 expression in primary Ta/T1 bladder cancer. J. Pathol. 209(1), 106–113 (2006).
  Medline CASGoogle Scholar
• 21 Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur. Urol. 46(2), 170–176 (2004).
  MedlineGoogle Scholar
• 22 Petty WJ, Voelzke WR, Urbanic JJ et al. High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer. Lung Cancer 74(3), 384–391 (2011).
  MedlineGoogle Scholar
• 23 Levidou G, Saetta AA, Karlou M et al. D-type cyclins in superficial and muscle-invasive bladder urothelial carcinoma: correlation with clinicopathological data and prognostic significance. J. Cancer Res. Clin. Oncol. 136(10), 1563–1571 (2010).
  Medline CASGoogle Scholar
• 24 Wang W, Zhao LJ, Tan YX, Ren H, Qi ZT. MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 33(5), 1113–1120 (2012).
  Medline CASGoogle Scholar
• 25 Lopez-Beltran A. Bladder cancer: clinical and pathological profile. Scand. J. Urol. Nephrol. Suppl. 218, 95–109 (2008).
  MedlineGoogle Scholar
• 26 Lopez-Beltran A, Ordonez JL, Otero AP et al. Cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Arch. 457(5), 555–561 (2010).
  Medline CASGoogle Scholar
• 27 Su SF, de Castro Abreu AL, Chihara Y, Tsai Y et al. A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin. Cancer Res. 20(7), 1978–1989 (2014).
  Medline CASGoogle Scholar
• 28 Tilki D, Singer BB, Shariat SF et al. CEACAM1: a novel urinary marker for bladder cancer detection. Eur. Urol. 57(4), 648–654 (2010).
  Medline CASGoogle Scholar
• 29 Horstmann M, Patschan O, Hennenlotter J, Senger E, Feil G, Stenzl A. Combinations of urine-based tumour markers in bladder cancer surveillance. Scand. J. Urol. Nephrol. 43(6), 461–466 (2009).
  MedlineGoogle Scholar
• 30 Schmitz-Drager BJ, Todenhofer T, Van Rhijn B et al. Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. Urol. Oncol. 32(7), 1061–1068 (2014).
  MedlineGoogle Scholar